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Abstract
Epidemiologic studies correlate low vitamin C intake with bone loss. The genetic deletion of enzymes involved in de novo
vitamin C synthesis in mice, likewise, causes severe osteoporosis. However, very few studies have evaluated a protective role
of this dietary supplement on the skeleton. Here, we show that the ingestion of vitamin C prevents the low-turnover bone
loss following ovariectomy in mice. We show that this prevention in areal bone mineral density and micro-CT parameters
results from the stimulation of bone formation, demonstrable in vivo by histomorphometry, bone marker measurements,
and quantitative PCR. Notably, the reductions in the bone formation rate, plasma osteocalcin levels, and ex vivo osteoblast
gene expression 8 weeks post-ovariectomy are all returned to levels of sham-operated controls. The study establishes
vitamin C as a skeletal anabolic agent.
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Introduction
The diligent search for small molecules and biologics to treat
osteoporosis resonates with the expanding definition of osteopo-
rosis and the implication that many more individuals worldwide
have fragile bones. In developing nations in particular, while
disease prevalence is difficult to estimate short of bone density
measurements, the growing incidence of fractures poses a heavy
burden of healthcare costs. In China, for example, almost 69
million individuals are estimated to have osteoporosis [1]. The cost
of non-generic medications becomes difficult to bear in such
emerging economies, prompting the need for affordable ‘‘osteo-
protection’’.
Vitamin C has long been known to affect the skeleton as gross
deficiency causes the brittle bones of scurvy [2]. However, over the
past decade, more subtle effects of vitamin C undernutrition have
been gleaned. For example, low vitamin C intake is associated with
low bone mass and a high fracture risk [3,4]. More importantly,
persuasive epidemiological evidence suggests that higher vitamin
C intake is associated with higher bone mass [5], as well as
reduced fracture risk over a 17-year follow-up [6]. Likewise, the
Women’s Health Initiative found a statistical relationship between
total vitamin C intake and bone mineral density at both the hip
and spine in women receiving hormone therapy [7]. Thus, it
appears that, while adequate vitamin C prevents scurvy, higher
doses might protect against skeletal loss.
Further evidence for an effect of vitamin C on bone mass comes
from mouse genetic studies. The deletion of two key enzymes
aldose reductase and aldehyde reductase, which results in absent de
novo synthesis of ascorbic acid in mice, causes scorbutic bones [8].
While humans have lost the ability to synthesize vitamin C in vivo,
and thus require nutritional supplementation, data in mice firmly
establish an indispensible role for vitamin C in skeletal homeo-
stasis. Both mouse and human osteoblasts require ascorbic acid to
differentiate into mature mineralizing cells [9,10]. In addition,
mice that genetically lack ascorbic acid have immature dysplastic
osteoblasts [8]. Thus, a key target for vitamin C appears to be the
osteoblast. However, vitamin C also alters the resorption of bone
by osteoclasts [11].
Importantly, Chambers and colleagues found that intraperito-
neally injected ascorbic acid (2 mmol/kg/day) prevented ovariec-
tomy-induced hyper-resorption and bone loss [12]. This study
provided proof-of-concept that vitamin C could potentially be
used to prevent hypogonadal bone loss. Still, even with the passage
of ,20 years, no clinical trials have evaluated the effect of vitamin
C on skeletal integrity in humans. Here, we extend Chambers’
initial observation, and provide evidence that vitamin C, when
ingested orally, can prevent bone loss following ovariectomy
through an anabolic action. We show, in a model of low-turnover
osteoporosis, that this in vivo action results from the stimulation of
bone formation noted in histomorphometric, bone marker, and
quantitative PCR (qPCR) studies. Together with prior epidemi-
ologic evidence showing a relationship between dietary intake and
bone mass, our data provide compelling evidence for a therapeutic
potential for vitamin C.
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Results
Groups of 6 month-old female C56/BL6 mice were ovariecto-
mized or sham-operated and given vitamin C (5 mg/day) in
drinking water ad libitum. Areal bone mineral density (BMD) was
measured by Piximus (Lumar GE) at 0, 4 and 8 weeks, following
which bones were harvested for micro-CT (Scanco mCT40) and
histomorphometry measurements. Additionally, harvested bone
marrow stromal cells were cultured in the absence of ascorbic acid
for 6 and 10 days, following which qPCR was performed on the
extracted RNA [13].
At both 4 and 8 weeks of treatment, there was a significant
decrease in areal BMD at the lumbar spine (L4–L6) in
ovariectomized mice compared with sham-operated controls
(Figures 1B and 1C). Whereas vitamin C did not elevate lumbar
spine BMD in sham-operated mice, it prevented the lumbar spine
BMD loss following ovariectomy (Figures 1B and 1C). Thus, there
was a significant difference between BMD in ovariectomized mice
and ovariectomized mice treated with vitamin C (Figures 1B and
1C). In contrast to the lumbar spine (L4–L6), which represents
largely trabecular bone, BMD at cortical bone-rich sites, such as
the femur, was reduced significantly only at 8 weeks post-
ovariectomy (Figure 1C). This decline was prevented in vitamin C-
treated ovariectomized mice, but the difference did not reach
statistical significance (Figure 1C). In contrast, minimal, statisti-
cally insignificant, decrements in tibial BMD were noted at 8
weeks; this change was prevented with vitamin C so that there was
a statistically significant difference between tibial BMD in
ovariectomized mice and ovariectomized mice treated with
vitamin C (Figure 1C). These data are consistent with the
relatively minimal effects of ovariectomy on cortical bone over 8
weeks.
Micro CT analysis of the lumbar spine (L3) revealed that both
BMD and BV/TV were reduced significantly upon ovariectomy
(Figures 2A and 2B). However, while BV/TV prevented with
vitamin C treatment, there was a statistically insignificant
(p = 0.137) increase in volumetric BMD (Figures 2A and 2B).
Likewise, trabecular number (Tb.N) was expectedly reduced and
trabecular spacing (Tb.Sp) increased upon ovariectomy (Figure 2C
and 2E). Only the decrement in Tb.N was, however, prevented
with vitamin C treatment (Figure 2C). Figure 3A shows a two-
dimensional view of the trabecular structure of bone that is
dramatically reduced following ovariectomy and this effect was
prevented with vitamin C treatment.
Figure 3 also shows data from dynamic histomorphometry of
the lumbar spine. Calcein labeling was markedly reduced upon
ovariectomy (Figure 3B), apparent as a profound reduction in
mineralizing surface (MS), mineral apposition rate (MAR) and
bone formation rate (BFR) (Figures 3C, 3D and 3E). No change in
tartrate-resistant acid phosphatase (TRAP) labeled surfaces
(Resorbed S./BPm) were noted when ovariectomized mice were
compared with sham-operated controls (Figure 3F). The latter is
not unexpected after 8 weeks of ovariectomy, when the initial
hyper-resorption slows down and is accompanied by a decrease in
bone formation – hallmarks of low-turnover osteoporosis [14].
Concordant results – notably a significant decline in plasma
osteocalcin and a trend towards reduced plasma C-telopeptide –
were noted upon ovariectomy (Figure 3G and 3H).
Vitamin C treatment completely prevented the reductions in
MS, MAR and BFR to levels that were not significantly different
from sham-operated controls (Figure 3C, 3D and 3E). This was
paralleled by a similar reversal in plasma osteocalcin to control
levels, with the difference that the treatment of sham-operated
controls with vitamin C also significantly elevated plasma
osteocalcin compared with the sham-operated controls
(Figure 3G). Together, the data provide evidence for an anabolic
action of vitamin C both in basal and ovariectomized states. No
significant changes in resorption were noted upon vitamin C
treatment, either in terms of resorbed S./BPm or plasma C-
telopeptide levels (Figure 3F and 3H).
Figure 1. Oral Vitamin C Prevents Ovariectomy-Induced Bone
Loss in Mice. Bone mineral density (BMD) measurements by Piximus
(GE Lunar) at the total body, and the lumbar spine (L4–L6), left femur
and tibia, measured 0, 4 and 8 weeks following ovariectomy (OVX) or
sham operation (C) in 6 month-old mice. The mice were allowed to
ingest vitamin C (VC) (5 mg/day) in drinking water ad libitum. Statistics:
comparisons were made for differences between ovariectomized and
sham-operated mice (*p,0.05, **p,0.01), and within the sham-
operated and ovariectomized groups, between vitamin C treated and
controls (ˆp,0.05, ˆˆp,0.01); n = 5 mice per group.
doi:10.1371/journal.pone.0047058.g001
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To obtain a long-term genetic imprint for the action of vitamin
C, when administered in vivo, bone marrow stromal cells were
cultured in the absence of ascorbic acid for 6 or 10 days. There
were profound increases in the expression of the bone sialoprotein
protein gene at both time points, whereas the early bone morphogenetic
protein-2 gene showed a significant increase at day 6, with minimal
increases at day 10 (Table 1). While Runx2 expression was
unresponsive at day 6 of culture, vitamin C ingestion by sham-
operated or ovariectomized mice triggered a significant increase in
Runx2 mRNA at day 10 (Table 1). Expression of the osterix and
alkaline phosphatase genes were more sensitive to stimulation in
sham-operated than in ovariectomized mice (Table 1); the reason
for this difference is unclear. Despite the variations in the
responsiveness of the respective genes to vitamin C, which may
represent temporal expression differences, the data suggests that
the vitamin C, administered in vivo, is a potent stimulator of
osteoblast differentiation. The genetic imprint of this action is
notable even after 10 days of ex vivo culture of stromal cells without
added vitamin C.
Discussion
We examined the in vivo skeletal anabolic action of vitamin C in
low-turnover osteoporosis induced 8 weeks following ovariectomy
in mice [14]. In these mice, bone formation declined, whereas
minimal changes were noted in resorption parameters. We show
that vitamin C prevents bone loss in this model via a potent pro-
osteoblastic action. This, however, does not rule out actions of
vitamin C on bone resorption. A particular caveat is that earlier,
strong transient increases in resorption post-ovariectomy have not
been sampled in our study, while their inhibition may contribute
to the effect of vitamin C on bone mass. Indeed, there is no doubt
that vitamin C reduces bone resorption in high-turnover states,
primarily by inhibiting osteoclastogenesis and promoting osteoclast
apoptosis [11,12,15–17]. We have shown previously that the pro-
osteoclastogenic effects of TNF-a are prevented by vitamin C [18].
Here, we show that ingested vitamin C additionally stimulates
bone formation in vivo, likely by inducing the osteoblast to
differentiate into a mature, mineralizing phenotype.
Our data complement the elegant loss-of-function studies by
Gabbay and coworkers [8], in which they document a role for
endogenous ascorbic acid on bone mass and bone remodeling in
mice. They find that genetically deleting aldehyde reductase, an
enzyme responsible for ,85% de novo ascorbic acid synthesis,
results in profound osteopenia, mainly due to reduced bone
formation [8]. They identify dysplastic proliferating mesenchymal
cell masses in nasal turbinates, reminiscent of similar masses seen
the GLUO-deficient, scorbutic mouse [19]. They also note that
castration further lowers bone mass, and is accompanied by severe
osteoclastic bone resorption, which is rescued by feeding mice with
ascorbic acid (1% chow pellets). As noted above, our complemen-
tary gain-of-function studies using a mouse model of low-turnover
osteoporosis does not allow us to pin point the anti-resorptive
actions of vitamin C. Instead, they reinforce the concept that
ascorbic acid can also prevent bone loss through an anabolic
action. Such anabolic actions have long been predicted from in
vitro studies, towards which several molecular mechanisms have
been proposed [9,10,20,21]. Most notably, vitamin C is known to
function as a co-factor for lysine and proline hydroxylation during
type 1 collagen synthesis [22].
The ingested dose of vitamin C in our studies is 10-fold higher
than over-the-counter doses (1000 mg) used as dietary supple-
ments in humans. However, as mice synthesize the human body
weight equivalent of 10,000 mg per day [23], a normal human
daily dose of 1000 mg was considered insufficient to elevate
concentrations above basal circulating levels in mice. Thus, we
utilized a higher dose than the normal human dose, noting that
Chambers and co-workers used an even higher dose, ,1.7-fold
Figure 2. Oral Vitamin C Prevents Structural Deterioration in Ovariectomized Mice. Measurements by micro-CT (Scanco mCT40) of static
parameters, including bone mineral density (volumetric) (A), bone volume fraction (BV/TV) (B), trabecular number (TbN) (C), trabecular thickness
(TbTh) (D), trabecular spacing (TbS) (E), and bone volume (BV) (F), measured 8 weeks following ovariectomy (OVX) or sham operation (C) in 6 month-
old mice. The mice were allowed to ingest vitamin C (VC) (5 mg/day) in drinking water ad libitum. Panel G shows representative m-CT images from the
respective groups. Statistics: comparisons were made for differences between ovariectomized and sham-operated mice (*p,0.05, **p,0.01), and
within the sham-operated and ovariectomized groups, between vitamin C treated and controls (ˆp,0.05, ˆˆp,0.01); n = 5 mice per group.
doi:10.1371/journal.pone.0047058.g002
Vitamin C and Bone Loss
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higher (2 mmol/kg/day) than ours, to prevent bone loss in high-
turnover osteoporosis [12]. This dose caused a ,30% increase in
circulating vitamin C levels.
There are very few therapies that selectively target low-turnover
bone loss, such as that occurring with age and after high-dose
glucocorticoid therapy [24]. The dysfunction or premature demise
Figure 3. Oral Vitamin C Stimulates Bone Formation in Ovariectomized Mice. Representative reverse phase contrast (showing trabecular
structure) (A) and fluorescence micrographs (showing calcein labels) (B) 8 weeks following ovariectomy (OVX) or sham operation (C) in 6 month-old
mice. The mice were allowed to ingest vitamin C (VC) (5 mg/day) in drinking water ad libitum. Measurements of dynamic parameters, including
mineralizing surface (MS) (C), mineral apposition rate (MAR) (D), bone formation rate (BFR) (E) and tartrate-resistant acid phosphatase- (TRAP-) labeled
surfaces (Resorbed S./BPm) (F). Markers of bone turnover measured in plasma, namely osteocalcin (formation) (G) and C-telopeptide (resorption) (H).
Statistics: comparisons were made for differences between ovariectomized and sham-operated mice (*p,0.05, **p,0.01), and within the sham-
operated and ovariectomized groups, between vitamin C treated and controls (ˆp,0.05, ˆˆp,0.01); n = 5 mice per group.
doi:10.1371/journal.pone.0047058.g003
Vitamin C and Bone Loss
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of osteoblasts in these conditions is a hallmark, reflected clinically
in low bone formation markers. While anti-resorptive agents, such
as bisphosphonates, that target the osteoclast, do reduce fracture
risk even in low-turnover states, there are practical limits to their
efficacy [25]. Anabolic agents, such as recombinant human
parathyroid hormone (PTH) and a future anti-sclerostin antibody,
make good pathophysiologic sense for use in these conditions.
Vitamin C, through a combination of its known anti-resorptive
action and the anabolic effect shown herein, may have a more
profound effect on the skeleton.
However, it is possible that higher doses of vitamin C will be
utilized compared with those recommended by the Institute of
Medicine [26] or those offered in over-the-counter supplements.
As a water-soluble vitamin, excess vitamin C is excreted in urine,
and cases of vitamin C toxicity are therefore rare. The tolerable
upper limit of intake of vitamin C is 2000 mg per day [26].
Beyond this level, rare side effects include mild gastrointestinal
symptoms, such as abdominal cramps. However, reports for
increased risk of kidney stones and of cardiovascular disease in
postmenopausal women with diabetes are conflicting and incon-
clusive. It would nonetheless be worthwhile examining lower doses
for additive or synergistic effects, particularly as adjuncts to current
anti-resorptive and/or anabolic therapies. This begs the need for
future dose-ranging and safety studies on vitamin C in humans.
Materials and Methods
All animal studies were approved by the Institutional Animal
Care and Use Committee at Mount Sinai School of Medicine and
were performed in accordance with the guidelines of the National
Institutes of Health and Mount Sinai School of Medicine.
The dose of vitamin C in our studies was 10-fold higher than
over-the-counter doses (1000 mg) used as dietary supplements.
However, a daily dose of 1000 mg was considered insufficient as
mice synthesize the human body weight equivalent of 10,000 mg
per day [23]. Chambers and co-workers used an even higher dose,
,1.7-fold higher (2 mmol/kg/day) than ours [12]. This dose
caused a significant (p = 0.038, by ANOVA, n= 19) ,30%
increase in circulating vitamin C levels from a mean (6SEM,
mg/mL) of 30.4 (63.54) to 39.2 (63.51) (VITAMIN C ELISA,
Biotang, Boston, MA). This suggests that the oral vitamin C dose
was not only optimal in producing a significant change in serum
vitamin C levels, but also efficacious in preventing ovariectomy-
induced bone loss.
Areal bone mineral density (BMD) measurements were
performed on C57/BL6J mice (Jackson Laboratories, Bar Harbor,
ME) using a small animal bone densitometer (Piximus, Lunar-GE)
[27]. Whole body BMD (minus cranium), and region-specific
measurements of the spine (L4–L6), left femur, and left tibia were
made. The instrument was calibrated each time before use by
employing a phantom per manufacturer’s recommendation.
For micro-CT estimations, the L3 vertebra was scanned non-
destructively by using a Scanco mCT scanner (mCT-40; Scanco
Medical AG, Bassersdorf, Switzerland) at 12 mm isotropic voxel
size, with X-ray source power of 55 kV and 145 mA, and
integration time of 300 milliseconds. The trabecular microstruc-
ture of the entire secondary spongiosa of L3 between the cranial
and the caudal area was evaluated. The scanned grey-scale images
were processed by using a low-pass Gaussian filter (sigma=0.8,
support = 1) to remove noise, and a fixed threshold of 220 was
used to extract the mineralized bone from soft tissue and the
marrow phase. The reconstruction and 3D quantitative analyses
were performed using software provided by Scanco. The same
settings for scan and analysis were used for all samples. Trabecular
bone parameters included volumetric bone mineral density
(BMD), bone volume (BV), bone volume fraction (BV/TV),
trabecular thickness (Tb.Th), trabecular number (Tb.N), and
trabecular spacing (Tb.Sp) (units specified in Figure 2).
Bone formation and resorption rates were quantitated by
dynamic histomorphometry following two sequential injections of
calcein (15 mg/kg) five days apart before sacrifice. Parameters
included mineralized surface (MS), mineral apposition rate
(MAR), bone formation rate (BFR), and TRAP surfaces (Resorbed
S./BPm) [27]. Bone turnover markers, namely osteocalcin and C-
telopeptide, were measured on mouse plasma using commercial
kits (Mouse Osteocalcin kit, Biomedical Technologies, Stoughton
MA, BT-470 and RatLaps EIA, Immunodiagnostics Systems, AC-
06F1, respectively). Bone marrow was isolated and stromal cell
cultures performed in the absence of ascorbate for 6 or 10 days.
RNA was extracted for quantitation of gene expression using
established protocols [13]. Quantitative PCR was performed as
described [13]. L-ascorbic acid was purchased from Sigma.
The data were analyzed using Student’s t-test with Bonferroni’s
correction. In every case, comparisons have been made for
differences between ovariectomized and sham-operated mice to
examine the effect of ovariectomy. Furthermore, within the sham-
operated and ovariectomized groups, comparisons were made for
differences between vitamin C treated and control mice. Results
were considered significant if p,0.05.
Table 1. Oral Vitamin C Stimulates the Expression of Osteoblast Differentiation Genes.
Day 6 Day 10
Sham OVX Sham OVX
VC 0 5 0 5 0 5 0 5 mg/day
BSP 1.00 60.10 5.05 60.37 ** 1.00 60.08 4.57 60.37 ** 1.00 60.07 16.8 61.14 ** 1.00 60.87 3.86 60.32 **
BMP2 1.00 60.20 1.19 60.32 1.00 60.11 6.92 61.13 ** 1.00 60.11 1.59 60.33 * 1.00 60.35 1.87 60.32
Runx2 1.00 60.11 0.90 60.45 1.00 60.05 1.21 60.27 1.00 60.06 2.17 60.15 ** 1.00 60.50 1.94 60.21 **
Osterix 1.00 60.18 1.47 60.17 1.00 60.52 0.83 60.06 1.00 60.08 3.81 60.11 ** 1.00 60.50 1.63 60.08 **
ALP 1.00 60.06 2.68 61.01 1.00 60.06 0.85 60.07 1.00 60.06 4.24 60.78 ** 1.00 60.39 1.42 60.49
Quantitative PCR (qPCR) on RNA isolated from bone marrow stromal cells harvested from mice that were fed with vitamin C (5 mg/day, VC) following ovariectomy (OVX)
or sham operation (Sham). The cells were cultured in ascorbate-free medium for 6 or 10 days following which the expression of several osteoblast differentiation genes
and transcription factors, namely bone sialoprotein (BSP), bone morphogenetic protein-2 (BMP2), Runx2, osterix, and alkaline phosphatase (ALP) were quantitated. Statistics:
mean6SEM; comparisons between vitamin C-treated and untreated groups (*p,0.05, **p,0.01); qPCR in triplicate; n = 5 mice per group (pooled).
doi:10.1371/journal.pone.0047058.t001
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